Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Joe E. who wrote (5678)	11/19/1998 7:54:00 AM
From: John F Beule	Respond to of 6136

U.S. States Demand Lower Price for DuPont's Sustiva, WSJ Says Washington, Nov. 19 (Bloomberg) -- Several U.S. states, including New York and California, are refusing to pay for DuPont Co.'s HIV treatment drug Sustiva unless the company agrees to negotiate significant price discounts, the Wall Street Journal reported. Sustiva's annual wholesale price of $3,920 is almost twice as much as that of two other drugs that combat HIV, the virus that causes AIDS, which has angered state-run AIDS drug assistance programs responsible for purchasing medicines for uninsured people with HIV, the Journal said. Unidentified directors of state-run AIDS programs also met last week with unnamed officials of Glaxo Wellcome Plc to press for similar discounts on new drugs that company expects to sell soon, the Journal said. Earlier this month, the National Institute of Allergy and Infectious Diseases said it's preparing to study whether patients who have had very low levels of HIV for at least a year can stop taking medications and still keep the virus in check. (WSJ 11/19 A8 www.wsj.com) 07:27:42 11/19/1998 Any redistribution of Bloomberg content, including by framing or similar means, is expressly prohibited without the prior written consent of Bloomberg L.P. Any reference to the material must be properly attributed to Bloomberg News. The information herein was obtained from sources which Bloomberg L.P. and its suppliers believe reliable, but they do not guarantee its accuracy. Neither the information, nor any opinion expressed, constitutes a solicitation of the purchase or sale of any securities or commodities.(C) Copyright 1998 Bloomberg L.P. BLOOMBERG, Bloomberg News, Bloomberg Financial Markets, Bloomberg Television, Bloomberg News Radio are trademarks, tradenames and service marks of Bloomberg L.P.